Revive Therapeutics Ltd C.RVV

Alternate Symbol(s): RVVTF

Healthcare

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions or Long COVID. It also advancing the development of Psilocybin-based therapeutics through various programs. The Company's subsidiaries include Revive Therapeutics Inc. (Ontario), Revive Diagnostics Inc., and Psilocin Pharma Corp. (Ontario).

CSE:RVV - Post by User

Revive Therapeutics Ltd > FDA Expanded Access Program

<< Previous

Bullboard Posts

Next >>

Comment by PowerofNowon Aug 26, 2020 1:37pm

84 Views

Post# 31456529

RE:FDA Expanded Access Program

Here we go talking FACTS not CHIRP
https://www.fda.gov/medical-devices/investigational-device-exemption-ide/expanded-access-medical-devices

mrnormal wrote:
What this means is that after early positive analysis during the Phase 3 trial, done by Advarra, a premier IRB services company in North America, Revive and the FDA will allow Bucillamine to market for licensed physicians in the US so that they DO NOT have to wait for the full study to be complete. Which means that Bucillamine should start helping save lives as early as mid-September!

Also note: Revive expects to have Covid use patients enrolled in September 2020.

Quote:
Study of Bucillamine...will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days.